一种肝细胞肝癌诊断和预后的tsRNA生物标志物及其应用
By combining the 5'-tiRNA-iMet-CAT biomarker with high-throughput sequencing and RT-qPCR technology, a diagnostic kit for hepatocellular carcinoma was developed, solving the problem of early diagnosis, achieving efficient screening and diagnosis of hepatocellular carcinoma, and improving the sensitivity and specificity of diagnosis.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- AFFILIATED HOSPITAL OF NANTONG UNIV
- Filing Date
- 2025-09-16
- Publication Date
- 2026-07-17
AI Technical Summary
The lack of effective early diagnostic methods and biomarkers for screening hepatocellular carcinoma in current technologies leads to most liver cancer patients being diagnosed at an advanced stage, resulting in a low five-year survival rate.
Using 5'-tiRNA-iMet-CAT as a biomarker, differential expression profiles of tsRNA in hepatocellular carcinoma tissues and adjacent normal tissues were constructed by high-throughput sequencing. Combined with RT-qPCR detection, reagents and kits for the diagnosis of hepatocellular carcinoma were developed, and AFP and PIVKA-II were used in combination for diagnosis.
It enables early diagnosis of hepatocellular carcinoma, with an AUC of 0.909 distinguishing hepatocellular carcinoma patients from healthy individuals in serum, and a sensitivity and specificity of 85% and 80%, respectively. When used in combination, the AUC can reach 0.960, and the sensitivity and specificity can reach 95% and 68%, respectively, which significantly improves the diagnostic efficacy.
Smart Images
Figure CN121137151B_ABST